TY - JOUR T1 - Downregulation of <sup>18</sup>F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1815 LP - 1819 DO - 10.2967/jnumed.109.065367 VL - 50 IS - 11 AU - Lucia Nogová AU - Ronald Boellaard AU - Carsten Kobe AU - Nikie Hoetjes AU - Thomas Zander AU - Stefan Hubert Gross AU - Sasa Dimitrijevic AU - Theodore Pellas AU - Wolfgang Eschner AU - Katja Schmidt AU - Christopher Bangard AU - Wendy Hayes AU - Roman K. Thomas AU - Markus Dietlein AU - Giuseppe Giaccone AU - Otto S. Hoekstra AU - Adriaan A. Lammertsma AU - Jürgen Wolf Y1 - 2009/11/01 UR - http://jnm.snmjournals.org/content/50/11/1815.abstract N2 - Everolimus downregulates glucose metabolism–associated genes in preclinical models. Inhibition of glucose metabolism measured by 18F-FDG PET was postulated to serve as a pharmacodynamic marker in everolimus-treated non–small cell lung cancer (NSCLC) patients. Methods: In 8 NSCLC patients treated with everolimus, the percentage change in 18F-FDG PET uptake (days 8 and 28 relative to baseline) was determined using a variety of summed standardized uptake value (SUV) measures. Both maximum and mean SUVs were used, with normalizations to body surface area and body weight and with and without correcting for plasma glucose levels. Results: In 5 patients, a reduction of 18F-FDG PET uptake on day 8 was observed with all methods, ranging from −12.8% to −72.2%. Conclusion: These observations demonstrate that inhibition of glucose metabolism is an early effect of everolimus treatment in NSCLC patients and can be assessed using 18F-FDG PET. ER -